Clinical trials: Early Alzheimer's Disease
Alzheimer's Disease
[18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease
To investigate the primary brain regions of precursors of Alzheimer's disease and Alzheimer's disease by novel molecular probe [18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT imaging.
- Trial name
- NCT06833645
- Testing
- molecular probe [18F]AV45(Aβ) and [18F]AV1451(Tau)
- Where
- China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Sichuan Provincial People's Hospital
Alzheimer Disease, Early-Onset
Examining Neuroinflammation in AlzHeimer's
Alzheimer disease (AD) is a neurodegenerative disorder with a poorly understood pathology. It is an irreversible progressive brain disease that slowly deteriorates memory, thinking and behavior.
- Trial name
- ENHANCE (NCT03548883)
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AdventHealth
Alzheimer's Disease
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA…
- Trial name
- NCT06322667
- Testing
- No Intervention
- Where
- 3 sites in Japan
- Volunteers
- 5,000 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer Disease, Battery
Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development
The early assessment of new drugs for Alzheimer's disease remains difficult because of the lack of predictive end-point. The use of a battery including different parameters could improve this early development of new drugs.
- Trial name
- PharmacogWP3 (NCT01487395)
- Testing
- Donepezil .
- Where
- 3 sites in France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- NPC1-AD (NCT07236190)
- Testing
- natural product combination-1 (NPC1)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Alzheimer Disease
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
The purpose of this study is to assess the efficacy of paper-based cognitive training in Vietnamese patients with early Alzheimer's disease
- Trial name
- NCT04949750
- Testing
- Paper - based cognitive training
- Where
- Vietnam
- Volunteers
- 70 people
- Sponsor
- University of Medicine and Pharmacy at Ho Chi Minh City
Cognitive Impairment, Alzheimer Disease, Early Onset
Juice Plus Supplement Clinical Trial
The study is designed to determine whether encapsulated fruit and vegetable juice concentrates can improve biological indicators of cognitive and multiple dimensions of memory and learning.
- Conditions
- Cognitive Impairment, Alzheimer Disease, Early Onset, Mild Cognitive Impairment
- Trial name
- NCT04656860
- Testing
- Juice Plus+
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Alabama, Tuscaloosa
Alzheimer's Disease
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region…
- Trial name
- NCT06602258
- Testing
- E2814, Lecanemab
- Where
- 26 sites in United States, Japan
- Volunteers
- 105 people
- Sponsor
- Eisai Inc.
Alzheimer
ALZEVIT: Nationwide Digital APOE ε4 Cohort for Early Alzheimer's Disease Prevention and Trial Readiness
ALZEVIT is a nationwide, decentralized, digital-first cohort study in France designed to establish a large-scale Apolipoprotein E (APOE) genotyping registry and enable precision prevention strategies for Alzheimer's disease (AD).
- Trial name
- ALZEVIT (NCT07679906)
- Where
- France
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Firalis SA
Alzheimer's Disease
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as…
- Trial name
- EMERGE (NCT02484547)
- Testing
- Aducanumab (BIIB037)
- Where
- 180 sites in United States, Belgium and 11 more
- Volunteers
- 1,643 people
- Sponsor
- Biogen
Alzheimer Disease, Early Onset, Parkinsons Disease with Dementia
Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease
The goal of this Multicenter observational pilot study is to Compare the specifics of musical engagement (behaviors related to music in everyday life) in subjects aged over 60 with Alzheimer s disease, Parkinson s disease and…
- Conditions
- Alzheimer Disease, Early Onset, Parkinsons Disease with Dementia, Non Pharmacological Intervention
- Trial name
- MUSENGAGE (NCT06688968)
- Testing
- neuropsychologist interview, questionnaire
- Where
- 3 sites in France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Alzheimer Disease, Mild Cognitive Impairment
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia.
- Trial name
- NCT06467539
- Testing
- DAOIB plus AO
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Chang Gung Memorial Hospital
Alzheimer Disease, Parkinson Disease
Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
Annovis is conducting a clinical study to investigate Posiphen in patients with Early Alzheimer's Disease (AD) and Early Parkinson's Disease (PD). Investigators are looking to recruit 68 patients in two parts of the study.
- Trial name
- NCT04524351
- Testing
- Posiphen
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- Annovis Bio Inc.
Alzheimer Disease, Biomarker in Early Diagnosis
miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction
Alzheimer's disease is the most common memory loss disease among the elderly. This disease affects the patient's memory, language, attention, and behavioral abilities.
- Trial name
- NCT07353502
- Testing
- Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Alzheimer Disease
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT06297590
- Testing
- LY3954068, Flortaucipir F18
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Alzheimer s Disease
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study
- Trial name
- NCT07764146
- Testing
- VY1706 Low dose, VY1706 Mid dose, VY1706 High Dose
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Voyager Therapeutics
Dementia, Alzheimer Disease
Integrating eSAGE With EHR Data Using Machine Learning for the Early Detection and Monitoring of Cognitive Impairment in Individuals
The goal of this observational trial is to leverage the electronic Self-Administered Gerocognitive Examination (eSAGE), a variety of metadata (a set of data that describes and gives information about other data) collected during…
- Conditions
- Dementia, Alzheimer Disease, Mild Cognitive Impairment, Worried Well
- Trial name
- NCT06017505
- Testing
- electronic self administered gerocognitive examination (eSAGE)
- Where
- United States
- Volunteers
- 1,486 people
- Sponsor
- Douglas Scharre
Alzheimer's Disease, Mild Cognitive Impairment
FluoroAv45 Imaging Research-in Alzheimer's Disease
Rationale: improving the early detection of AD at prodromal pre-dementia stages has become a major matter of concern. There is now an important body of literature stating that early isolated cognitive deficits (Mild Cognitive…
- Trial name
- FAIR-AD (NCT01325259)
- Testing
- neuropsychologic assessment, [18F]AV-45 PET, 18-FDG PET
- Where
- 4 sites in France
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Alzheimer's Disease, Progressive Primary Aphasia
tDCS Effect on Cognitive Functions From Patients With Alzheimer's Disease or Progressive Primary Aphasia
The purpose of this study is to evaluate the effect of 10 sessions of anodal transcranial Direct Current Stimulation (tDCS - 1 mA) applied to left Cortex DorsoLateral PreFrontal (CDLPF) of Alzheimer's or Primary Progressive…
- Conditions
- Alzheimer's Disease, Progressive Primary Aphasia, Early or Mild State
- Trial name
- ALSTICO (NCT02873546)
- Testing
- transcranial Direct Current Stimulation (tDCS)
- Where
- 3 sites in France
- Volunteers
- 52 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Alzheimer Disease
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
The objective of this study is to determine if comprehensive lifestyle changes may slow, stop, or reverse the progression of early-stage Alzheimer's disease.
- Trial name
- NCT04606420
- Testing
- Lifestyle medicine
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Preventive Medicine Research Institute